Kornimate/medical-research-clean huggingface dataset:
comparison of ilivtouch and fibroscan for the assessment of liver fibrosis and steatosis in adult patients in the us

Conditions: Liver Fibrosis; Fatty Liver

Summary: this is a multi-center, cross-sectional, and prospective study that will recruit patients from multiple hospitals or outpatient clinics in the usa to the comparison of ilivtouch and fibroscan for the assessment of liver fibrosis and steatosis in adult patients.

clinical phase: phase iv investigator-initiated study study centers planned: approximately 4 centers in different regions of the usa objectives: 1. primary objectives to evaluate the consistency of liver stiffness measurement (lsm) and ultrasound/controlled attenuation parameters (uap/cap) between ilivtouch-ft9000 and fibroscan 530 devices. 2. secondary objectives 1. to compare the operational features of the two devices, reflected in the success rate of examination and number of effective examinations. 2. to compare lsm obtained from each device with liver stiffness estimated by apri, fib-4, and safe scores. 3. the number of adverse events, serious events, and percentage of subjects with events will be calculated for ae, sae, ae of special interest, and ae leading to study withdrawal.

Eligibility criteria:
inclusion criteria: * a. adults aged above 18 years old who have at least one indication for te examination determined by the physicians; * b. patients who have test results for platelet count, alt, ast, globulin, hba1c, and total bilirubin (tbil) levels within 60 days; * c. patients who are willing to participate in the clinical study and can sign icf. exclusion criteria: * a. excessive drinking history within 90 days: for women-140 grams of alcohol per week or more; for men-210 grams of alcohol per week or more; * b. patients with alanine aminotransferase (alt) or aspartate aminotransferase ast \>100 u/ml (or 2.5 × upper limit of normal (uln) and/or total bilirubin (tbil) \> 1.8 mg/d (or \>1.5 × uln =1.2 mg/d); * c. patients with a history or current evidence of decompensated liver cirrhosis; * d. patients with various space-occupying tumors and cysts in the right liver; * e. patients with other serious systemically diseases or a history of malignant tumors; * f. patients with ascites; * g. patients with a non-healing wound on the right upper abdomen at this moment; * h. patients with intracavitary implantation of instruments; * i. pregnant women (urine pregnancy test should be performed for all women with child-bearing potential during screening); * j. any history of organ transplantation and existing functional grafts (except corneal or hair transplantation); * k. lack of or limited legal capacity.
neurofilaments for neda assessing in ms

Conditions: Multiple Sclerosis

Summary: goal is to evaluate the achievement of biological neda as demonstrated by a drop in neurofilament levels in ms patients commencing alemtuzumab therapy as part of their ms management.

primary 1. to evaluate the achievement of neda using blood and csf neurofilaments in alemtuzumab treated patients. secondary 2. to assess prognosis at the end of the study based on neurofilament status. 3. to correlate neurofilament levels with clinical and mri markers of disease activity. 4. to evaluate the effect of alemtuzumab on the profile of other csf, blood, urine, faeces biomarkers of inflammation, neurodegeneration, neuronal sprouting and synaptogenesis, treatment activity and metabolic activity.

Eligibility criteria:
inclusion criteria: 1. diagnosis of relapsing remitting multiple sclerosis (rrms). 2. age 18-55 years. 3. edss score between 0-5.5. 4. commencing alemtuzumab therapy at neurology infusion and planned investigation unit, the royal london hospital, ward 11d exclusion criteria: 1. a diagnosis of secondary progressive ms (spms) or other forms of progressive ms. 2. those unable to comply with study requirement
the effect of stress ball on copd patients receiving noninvasive mechanical ventilation support

Conditions: COPD; COPD Exacerbation

Summary: the aim of this randomised controlled trial was to investigate the effect of a stress ball on pain, anxiety and physiological parameters in chronic obstructive pulmonary disease (copd) patients on non-invasive mechanical ventilation (nimv).

continuous positive airway pressure (cpap) therapy used in nimv reduces the need for imv in copd patients and shortens hospital stays. negative states resulting from the difficulty of treatment lead to increased pain and anxiety in patients and negative results in vital signs. there is a need for non-invasive, low-cost and easy-to-use methods that can be used by nurses to address these problems in patients. this study will investigate the effect of a stress ball on changes in pain, anxiety and vital signs in patients diagnosed with copd and receiving cpap treatment during treatment. the stress ball will be applied to the patients during two consecutive cpap treatments and pain, anxiety scores and vital signs will be measured.

Eligibility criteria:
inclusion criteria: * diagnosed with copd * receiving cpap therapy * those who voluntarily agreed to participate in the study * turkish speaking, understanding, * no cognitive and cognitive problems * glasgow coma scale score of 13 and above * those who have not participated in stress ball etc. application before exclusion criteria: * refused to participate in the research * people with visual and hearing impairment * unable to speak and understand turkish * cognitive and cognitive problems * glasgow coma scale\<13 * infection, wound, burn, plaster, traction etc. in the hand and arm area * during the research, those who wanted to leave voluntarily * general condition deteriorated during nimv treatment

Keywords: anxiety pain cpap vital signs
satisfaction of patient with anaphylaxis in the use of a medical device

Conditions: Anaphylaxis

Summary: through several questionaries the investigators will measure the satisfaction of patients diagnosed with anaphylaxis in the use of a medical device for the adrenaline autoinjector, a smart case for an epinephrine autoinjector connected via bluetooth to a mobile application.


Eligibility criteria:
inclusion criteria: * patients 18 years old or above * patients diagnosed with anaphylaxis and an epinephrine auto-injector prescribed * patients with a smartphone * patients who signed the informed consent exclusion criteria: * patients who have not signed the informed consent * patients with some limitations for understanding or following correctly the trial procedures * pregnant or nursing women
the church as a bridge to deliver health resources via telehealth

Conditions: Obesity; Diet, Food, and Nutrition; Church; Healthcare Disparities; Minority Health; Mobile Health; Telehealth; Community-based Participatory Research; Primary Health Care; Weight Loss Programs; Health Behavior

Summary: the proposed church bridge intervention project will provide an innovative, evidence-based and technology supported, health intervention model for southern, african american, and rural populations who continue to be disparately burdened by obesity and associated co-morbidities (i.e., hypertension, diabetes, cardiovascular disease). by targeting young adults (21-50 years of age) with families, the project will contribute to the long-term reduction of preventable chronic disease and related health care costs for the public.


Eligibility criteria:
inclusion criteria: * bmi \>/=30 * must have elementary aged child (5-11 years) in household exclusion criteria: * any health condition where weight loss is contraindicated * complicated disease states (ie., advanced renal disease or heart failure)
quilt-3.026: amg 655 in combination with amg 479 in advanced, refractory solid tumors

Conditions: Colorectal Cancer; Locally Advanced; Metastatic Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Sarcoma; Solid Tumors

Summary: this is a multi-center, 2-part phase 1b/2 study of amg 655 in combination with amg 479 to be conducted in the united states and spain. part 1 is a dose escalation segment to identify a dose of amg 655 in combination with amg 479 that is safe and tolerable. part 2 will evaluate the safety and estimate the efficacy of amg 655 at the dose selected in part 1 in combination with amg 479 for the treatment of patients with advanced nsclc (non-squamous histology; squamous histology), crc, pancreatic cancer, ovarian cancer, and sarcoma.


Eligibility criteria:
inclusion criteria: * part 1: histologically or cytologically confirmed, locally advanced or metastatic, treatment-refractory solid tumors * part 2: histologically or cytologically confirmed, locally advanced or metastatic: nsclc (squamous or non-squamous cell carcinoma; up to 2 prior treatment regimens), colorectal cancer (up to 2 prior treatment regimens), pancreatic cancer (up to 1 prior treatment regimen), ovarian cancer (up to 2 prior treatment regimens), or sarcoma (up to 2 prior treatment regimens), according to cohort availability * eastern cooperative group (ecog performance status of 0 or 1 * women or men ≥16 years of age * adequate hematology, renal, hepatic, coagulation and glycemic function. exclusion criteria: * presence of uncontrolled central nervous system (cns) disease * systemic chemotherapy, hormonal therapy, immunotherapy, experimental or approved anticancer proteins/antibodies therapy ≤28 days before enrollment. * prior treatment with death receptor agonists (including but not limited to rhapo2l/trail \[amg951\], apomab, mapatumumab, lexatumumab, cs-1008) * prior treatment with igf receptor antagonists (including but not limited to cp-751, 871, mk0646, ave1642 or imc-a12)

Keywords: amg 655 amg 479 apoptosis monoclonal antibody tumor necrosis factor insulin-like growth factor
intratracheal umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia

Conditions: Bronchopulmonary Dysplasia; Extremely Premature Infants; Severe BPD That Conventional Therapies Has Failed; No Severe Congenital Anomalies; no Severe IVH Neither Cystic PVL

Summary: mesenchymal stem cells (mscs) have been reported to be effective to prevent alveolar growth arrest in experimental bronchopulmonary dysplasia (bpd). the aim is to treat the extremely premature infant with severe bpd to establish whether intratracheal instillation of umbilical cord-derived mscs (ucmscs) is safe and effective as a rescue treatment for severe bpd.


Eligibility criteria:
inclusion criteria: * severe bpd, defined by the national institute of child health and human development workshop, who conventional therapies (including furosemide and theophylline, and hfo ventilation) has failed exclusion criteria: * severe congenital anomalies * severe intraventricular hemorrhage ≥ grade 3 or cystic periventricular leukomalacia.

Keywords: bronchopulmonary dysplasia (bpd) extremely premature infant mesenchymal stem cells (mscs) umbilical cord
single loop djb sleeve gastrectomy for poorly controlled t2dm

Conditions: Diabetes Mellitus; Obesity; Bariatric Surgery Candidate; Weight Loss

Summary: type 2 diabetes mellitus (t2dm) is a chronic progressive illness affecting a substantial percentage of the general population. while pharmacotherapy remains the mainstay of treatment, around 60% of patients cannot achieve the recommended goals for diabetic control. weight control is a well-known essential component in normalizing blood glucose level in t2dm. the term metabolic surgery is recently introduced and it is now increasingly accepted as a valid option for obese t2dm patients with poor glycemic control despite optimal medical therapy. while laparoscopic roux-en-y gastric bypass (rygbp) is the gold-standard bariatric/metabolic procedure in many countries, it is not widely accepted in asia. recently, a novel bypass technique called single loop duodenojejunal bypass with sleeve gastrectomy (sldjb-sg) has been developed trying to tackle most drawbacks of rygbp. realizing there is a knowledge gap in applying the new duodenojejunal bypass procedure to obese t2dm patients, we propose to investigate and compare the efficacy of glycemic control and functional outcomes of sldjb-sg with conventional rygbp.

aim of study: to investigate and compare the safety profile, functional outcomes, efficacy in diabetic control and changes of hormonal profile of laparoscopic single loop duodenojejunal bypass plus sleeve gastrectomy (sldjb-sg) versus the conventional standard roux-en-y gastric bypass (rygbp). hypothesis: the efficacy of glycemic control and functional outcomes of sldjb-sg is better than conventional rygbp, and is a more suitable option for obese chinese diabetic patients.

Eligibility criteria:
inclusion criteria: * aged between 20 to 65 years * at least 2 years of t2dm * a bmi between 28 to 42 kg/m2 * a hba1c level above 7% despite multiple oral medications (\> 2) at higher than or equal to half-maximal dose, or already using insulin injection for more than 6 months * no active cardiovascular diseases, and * a asa grade ii or below * a fasting c-peptide \< 0.6ug/l exclusion criteria: * significant anaesthetic risk asa grade iii or above * history of diabetic ketoacidosis * uncontrolled dm with hba1c \> 12% * malignancy diagnosed within 5 years * chronic renal failure requiring dialysis * previous upper abdominal surgery affecting gastroduodenal configuration * major psychiatric illness including major depression and substance abuse * pregnancy or ongoing breast-feeding * inmates
review of the pathological results of appendectomy specimens

Conditions: Appendicitis; Pathology; Acute Appendicitis; Appendicitis (Diagnosis)

Summary: this is a retrospective review study to evaluate the histopathological findings post appendectomy

in this study, 940 cases will be reviewed. patient demographics, accuracy of imaging modalities, and histopathological findings will be described.

Eligibility criteria:
inclusion criteria: * patients underwent an appendectomy in king abdulaziz university hospital in the period between 2010-2017 exclusion criteria: * any other patients will be excluded from the study

Keywords: appendix pathology appendicitis diagnosis acute appendicitis
trial of collagen mesh for prevention of ventral hernia after surgery for advanced pelvic cancer

Conditions: Incisional Hernia; Pelvic Cancer

Summary: the aim of the present project is to investigate whether use of biological mesh at the donor site of the rotation flap in closure of the abdominal wall reduce the frequency of incisional hernia formation compared to the usual abdominal wall closure after abdominal rotation flap operation in surgery for advanced pelvic cancer.


Eligibility criteria:
inclusion criteria: * patients operated with a vertical rectus abdominis musculocutaneus flap after abdominoperineal resection for advanced pelvic cancer. exclusion criteria: * pre or perioperative knowledge of disseminated malignancy * unable to follow the control program * known allergy to pig * compromised immune defense * artificial heart valve or recent (\< 3 months) implanted foreign body * age \< 18 years

Keywords: vertical rectus abdominis musculocutaneus flap mesh repair salvage surgery
salivary markers in patients with xerostomia

Conditions: Xerostomia Due to Hyposecretion of Salivary Gland

Summary: the purpose of this study was to investigate the salivary levels of inflammatory and their association with oral health in xerostomía patient

primary outcome measures: * salivary proinflammatory and anti-inflammatory cytokines * questionnaire is provided to the patient for xerostomia characterization secondary outcome measures: * probing pocket depth * probing pocket depth and clinical attachment level * gingival index * plaque index * bleeding on probing

Eligibility criteria:
inclusion criteria: • the patient must have clinical symptoms of xerostomia (dry mouth) exclusion criteria: * head and neck radiotherapy * administration anti-inflammatory drugs or antibiotic therapies within the previous 6 months * patients who are unable or unwilling to cooperate * patient suffering from cancer

Keywords: saliva , dental , oral health
evaluation of clinical significance of circulating markers in breast cancer patients undergoing herceptin therapy

Conditions: Breast Cancer

Summary: about 30% of breast cancers have higher than normal levels of a cellular marker called her2. the amount of her2 is often measured in breast tissue. a higher level of this marker usually indicates a more aggressive type of breast cancer. cytokeratin is a second cellular marker found in breast cancer cells. detection of circulating cytokeratin in the blood could indicate the presence of cancer. the pathology department of the tom baker cancer center is doing this study to see if measuring the levels of circulating her2 and cytokeratin, through blood testing has clinical significance for patients with breast cancer.

* single variate analysis will be performed to correlate variables such as tumour size, grade, stage, er status, pr status and biopsy her2 status with soluble her2 levels. * soluble her2 levels will be analyzed as both a continuous and categorized variable. * the analysis will attempt to discern the relationship between soluble her2 levels, her2 positive circulating epithelial cell level and treatment response. * this will provide evidence of the effect various treatments have on her2 levels. her2 levels both in patients treated with herceptin and those on other treatment protocols, will be related to clinical disease measures such as time to progression, time to failure, duration of response and duration of survival. * an initial model of the relationship between these factors and soluble her2 as a marker will be established from the data.

Eligibility criteria:
inclusion criteria: * albertan women with breast cancer who will undergo herceptin therapy as part of their treatment at some point during a one-year period. exclusion criteria: * greater than 80 years of age * previous cancer diagnosis - (other than skin cancer)

Keywords: breast cancer herceptin therapy
the effects of vertebral manipulation and pain education in chronic neck pain

Conditions: Neck Pain

Summary: this study aims to investigate the effects of vertebral manipulation and pain education on subjects with neck pain. for this purpose, 90 subjects who present chronic neck pain will be selected and allocated randomly into 2 groups: vertebral manipulation group and pain education group.


Eligibility criteria:
inclusion criteria: * main complaint of neck pain for at least six (6) months; * score of at least 10 points in ndi (neck disability index); * pain and / or restriction of cervical movements; * pain reported at least 3 points on the nprs (numeric pain rating scale); * the definition of the term neck pain follows the classification of tfnp. exclusion criteria: * previous history of rheumatic disease, cervical myelopathy, tumors, vertebrobasilar insufficiency, central or peripheral neurological disorders; * history of major trauma, fracture or surgery in the neck, shoulder and/or upper limb; * signs of nerve root compression as important muscle weakness affecting the upper limbs, reduction, loss or increase of biceps and triceps reflexes, decreased sensation in the dermatomes of the upper limb; * red flags contraindicating spinal manipulation.
noise-induced hearing loss-acute exposure treatment

Conditions: Hearing Loss, Noise-Induced

Summary: the purpose of this study is to assess the safety and efficacy of zonisamide for the treatment of noise-induced hearing loss in adults.

this study is a randomized, double-blinded placebo-control trial with three parallel groups, to make use of a common control group. after being informed about the study expectations and potential risks, all individuals providing written informed consent will undergo screening to determine eligibility for study entry. participants who meet the eligibility requirements will be randomized in a balanced fashion into one of 3 arms: group 1) zonisamide 100 milligrams (mg) pre-op + placebo post-op; group 2) placebo pre- + placebo post-op; and group 3) zonisamide 100 mg post-op + placebo post-op

Eligibility criteria:
inclusion criteria: * patients who are scheduled to undergo a skull-based surgery that requires at least 45 minutes of surgical-drilling * at least 18 years of age * air conduction thresholds in the non-operated ears are to be no worse than 25 decibel (db) hearing loss (hl) for pure tone average 0.5, 1, and 2 kilohertz (khz) with no individual threshold greater than 30 db hl, and no worse than 45db hl at 4 khz at screening. * observed air-bone gap \< 10 db hl at 0.5, 1, 2, and 4 khz, with normal tympanometry. * ability to understand and willingness to sign an institutional review board (irb) approved written informed consent document. exclusion criteria: * history of known sulfa allergy or hypersensitivity to carbonic anhydrase inhibitors * history of moderate-to-severe kidney or liver disease * acute viral, bacterial, fungal or parasitic infection * history of seizures * currently pregnant or breast-feeding * any current or history of ear disorder and/or central auditory dysfunction in the non-operated ear * history of ototoxic drug use * current use of strong/moderate 3a4 inhibitor/inducer and grapefruit juice
prevention of constipation: systematic nursing interventions to reduce postoperative constipation after thoracic surgery

Conditions: Postoperative Constipation

Summary: the purpose of the study is to reduce the incidence of postoperative constipation by systematic nurse assessment, interventions and evaluation, in the first month after thoracic surgery.


Eligibility criteria:
inclusion criteria: * patients admitted for planned lung surgery * patients are capable * able to talk and understand danish exclusion criteria: * patients with colostomy and / or ileostomy * neurological or abdominal diseases * feed through a tube

Keywords: constipation cancer surgery intervention nursing postoperative
icg-pdt, periimplantitis, diabetes mellitus

Conditions: Peri-Implantitis

Summary: in this study, the effect of photodynamic therapy (indocyanine green mediated) on the clinical, biological and inflammatory aspects was assessed in diabetic patients having peri-implantitis


Eligibility criteria:
* inclusion criteria: * adult patients above 45 years of age having type 2 dm * hba1c (≥6.5%) and fasting glucose test * probing depth ≥6 mm with bleeding and/or suppuration on at least one site around dental implants that remained in situ * on radiographic assessment, the implants exhibited ≥ 3 mm alveolar bone loss apical to the coronal region of the intraosteal portion of the dental implant. * exclusion criteria patients were excluded if they indicated current or former history of tobacco smoking, any systemic disease other than dm, enrolled in a non-surgical periodontal maintenance program, history of implant repair, pregnancy, and part six months use of antimicrobials, non-steroidal anti-inflammatory drugs, bisphosphonates, or corticosteroids.

Keywords: photodynamic therapy* periimplantitis* diabetes mellitus* indocyanine green* photosensitizer*